Home / Stocks / Sun Pharmaceutical Ind L
SUNPHARMA

Sun Pharmaceutical Ind L Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,900.0

Change

+28.5 (1.52%)

Open

₹1,883.7

Prev. Close

₹1,871.5

Day High

₹1,914.8

Day Low

₹1,872.5

Volume Analysis

Traded

1,995,293

Delivered

1,057,880

Delivery %

53.02%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (29.0%)

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (0)

No signal for this stock

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,961.34 ₹1,938.07 ₹1,919.04 ₹1,895.77 ₹1,876.74 ₹1,853.47 ₹1,834.44
Fibonacci ₹1,938.07 ₹1,921.91 ₹1,911.93 ₹1,895.77 ₹1,879.61 ₹1,869.63 ₹1,853.47
Camarilla ₹1,911.63 ₹1,907.76 ₹1,903.88 ₹1,895.77 ₹1,896.12 ₹1,892.25 ₹1,888.37

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+10.39%

1 Week

+0.8%

1 Month

+8.88%

3 Months

-0.13%

6 Months

+3.0%

1 Year

+6.9%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹632.79

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

11.73%

Net margin 17.83% × asset turnover 0.51x × equity multiplier 1.29x

Company Overview

Sector

Healthcare

Market Cap

₹451,075 Cr

P/E (TTM)

36.7

ROE

16.0%

Book Value

₹372.0

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.

TopFund Analysis

Sun Pharmaceutical Ind L holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 73/100. The strongest factor is Financial Strength (100/100), while Valuation (32/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (29.0%); promoter holding is falling. FII holding has been falling.

TopFund Score — Fundamentals Quality

73/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

65

Valuation

32

Cash Flow

73

Corporate Governance

76

Momentum

64

Institutional Ownership

58

Business Quality

87

Risk & Volatility

78

Liquidity

83

From Screener.in

  • +Company is almost debt free.
  • +Company has been maintaining a healthy dividend payout of 34.1%
  • −Promoter holding has decreased over last quarter: -1.80%
  • −The company has delivered a poor sales growth of 11.8% over past five years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Sun Pharma clarifies Assam plant halt report concerns August 2026 developments, not a new event.

Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on November 2, 2026, with reference to news appeared in https://www.thehindu.com/ dated October 30, 2026 quoting …

Postal ballot completed on 31 Oct 2026; members approved ESOP 2026, borrowing limit and related resolutions.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 12,192 12,381 11,983 12,653 13,291 13,675 12,959 13,851 14,478 15,521 14,612 15,300 16,199
Expenses + 9,013 8,904 8,948 9,045 9,352 9,666 9,243 9,550 9,951 10,572 10,658 10,882 11,455
Operating Profit 3,179 3,477 3,035 3,608 3,939 4,009 3,716 4,302 4,527 4,948 3,954 4,418 4,744
OPM % 26.0% 28.0% 25.0% 29.0% 30.0% 29.0% 29.0% 31.0% 31.0% 32.0% 27.0% 29.0% 29.0%
Other Income + 294 180 504 533 354 149 251 -354 470 89 458 520 -752
Interest 49 35 74 62 69 52 49 75 100 78 86 100 75
Depreciation 633 622 650 655 626 631 664 701 730 732 775 739 758
Profit before tax 2,791 3,000 2,816 3,424 3,598 3,476 3,254 3,173 4,168 4,227 3,551 4,099 3,159
Tax % 14.0% 14.0% 5.0% 16.0% 16.0% 16.0% 34.0% 27.0% 25.0% 20.0% 23.0% 29.0% 37.0%
Net Profit + 2,385 2,561 2,659 2,861 3,037 2,913 2,154 2,293 3,125 3,381 2,710 2,901 1,995
EPS in Rs 10 11 11 12 13 12 9 10 13 14 11 12 8
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 11 10 10 6 9 10 8 9 9 13 13 10 12

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 27,392 28,487 31,578 26,489 29,066 32,838 33,498 38,654 43,886 48,497 52,578 58,462 61,631
Expenses + 19,498 20,313 21,476 20,858 22,689 25,855 25,028 28,397 32,235 35,479 37,464 41,961 43,567
Operating Profit 7,894 8,174 10,102 5,631 6,377 6,983 8,470 10,258 11,650 13,018 15,114 16,501 18,064
OPM % 29.0% 29.0% 32.0% 21.0% 22.0% 21.0% 25.0% 27.0% 27.0% 27.0% 29.0% 28.0% 29.0%
Other Income + 283 -42 610 -135 -258 382 -3,449 -3,505 459 865 1,444 1,895 316
Interest 579 523 400 518 555 303 141 127 172 238 231 339 339
Depreciation 1,195 1,038 1,265 1,500 1,753 2,053 2,080 2,144 2,529 2,557 2,575 2,938 3,005
Profit before tax 6,403 6,571 9,048 3,479 3,810 5,010 2,799 4,481 9,408 11,088 13,752 15,119 15,037
Tax % 14.0% 14.0% 13.0% 26.0% 16.0% 16.0% 18.0% 24.0% 9.0% 13.0% 20.0% 24.0% —
Net Profit + 5,476 5,658 7,846 2,542 3,208 4,172 2,272 3,389 8,513 9,610 10,965 11,509 10,987
EPS in Rs 22 19 29 9 11 16 12 14 35 40 46 48 46
Dividend Payout % 14.0% 5.0% 12.0% 23.0% 25.0% 25.0% 62.0% 73.0% 33.0% 34.0% 35.0% 33.0% —
Sales growth 70 4 11 -16 10 13 2 15 14 11 8 11 12

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 25,431 32,742 36,400 38,074 41,169 45,025 46,223 47,771 55,755 63,427 71,978 83,330 89,040
Borrowings + 8,996 8,497 9,832 10,385 10,514 8,315 3,869 1,290 6,886 3,274 2,362 4,627 3,241
Other Liabilities + 14,089 13,948 14,624 15,598 12,666 14,615 17,291 20,474 17,831 18,387 17,328 20,210 22,317
Total Liabilities 48,723 55,428 61,095 64,297 64,590 68,194 67,622 69,776 80,712 85,328 91,908 108,407 114,838
Fixed Assets + 12,682 15,872 17,675 18,853 21,837 22,847 21,553 22,665 24,065 23,248 22,586 32,822 35,110
CWIP 2,039 2,175 2,801 2,465 1,411 1,220 1,567 1,287 4,973 5,354 6,644 3,052 1,864
Investments 2,716 1,830 1,192 7,143 7,903 10,143 9,612 12,849 14,824 15,026 18,354 24,723 16,449
Other Assets + 31,286 35,550 39,427 35,837 33,439 33,984 34,890 32,975 36,849 41,700 44,324 47,811 61,415
Total Assets 48,723 55,428 61,095 64,297 64,590 68,194 67,622 69,776 80,712 85,328 91,908 108,407 114,838
Equity Capital 207 241 240 240 240 240 240 240 240 240 240 240 240

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 5,616 6,686 7,082 3,907 2,196 6,555 6,170 8,985 4,959 12,135 14,072 12,419
Cash from Investing Activity + -1,502 -3,949 -4,186 -3,104 -310 -2,225 407 -5,556 -7,220 -763 -5,183 -10,405
Cash from Financing Activity + -1,187 -1,889 -2,285 -1,539 -2,731 -5,715 -5,980 -5,193 2,376 -6,710 -7,906 -2,513
Net Cash Flow 2,927 848 611 -736 -844 -1,386 596 -1,765 115 4,662 983 -498
Free Cash Flow 3,316 3,353 3,492 2,013 -966 5,105 5,097 7,550 2,895 9,964 12,005 8,906
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 93 106 90 83 48 113 85 78 56 105 96 89

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 54.48% → 52.68%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 8.92% 8.97% 9.0% 8.89% 8.92% 8.86% 8.76% 8.72% 8.57% 8.48% 8.81% 10.7%
Promoters 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 52.68%
Government 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11% 0.0%
FII 17.08% 17.72% 17.23% 18.01% 18.04% 17.96% 17.26% 16.55% 16.12% 15.94% 14.54% 14.36%
DII 19.42% 18.71% 19.17% 18.48% 18.43% 18.58% 19.38% 20.12% 20.72% 21.0% 22.06% 22.27%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Sun Pharmaceutical Ind L (this stock) 451,075 36.7 5.05 16.0%
Divi S Laboratories Ltd 294,139 86.1 16.34 16.5%
Torrent Pharmaceuticals L 177,632 81.8 9.67 27.4%
Apollo Hospitals Enter. L 125,893 55.6 11.86 21.5%
Laurus Labs Limited 125,380 93.6 20.73 18.3%
Zydus Lifesciences Ltd 118,693 26.2 4.27 21.2%
Dr. Reddy S Laboratories 115,092 41.1 2.96 11.2%

Which Mutual Funds Hold Sun Pharmaceutical Ind L?

Frequently Asked Questions about Sun Pharmaceutical Ind L

Community Sentiment

What are other investors saying about Sun Pharmaceutical Ind L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.